Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Date:10/23/2007

NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Thursday, October 25, 2007 at 8:30 a.m. EDT to discuss the Third Quarter 2007 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-800-909-7113 (U.S.), 1-785-830-1914 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form n
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Digital Healthcare Conference 2007: Mounting obstacles for health IT
2. Biomedical engineering conference invites manufacturers
3. Conference to address small town development
4. Wisconsin to host SBIR Conference
5. Gaming conference explores interactive media in learning
6. Digital Healthcare Conference starts on a realistic note
7. Digital Healthcare Conference marks Wisconsins Healthcare IT Week
8. Third coast of biotechnology makes strong showing at VC conference
9. Why companies dont get invited to the DEMO conference
10. Giuliani will keynote RedPrairie Corporations user conference
11. Wicab to present BrainPort at Boston conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... DUBLIN , May 05, 2015 Research ... announced the addition of the "Clinical Laboratory, ... and Forecast 2015 to 2019 - Global Version" ... technical developments especially in the area of molecular ... dynamic, growing and evolving world market that is ...
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire/ ... today announced that David R. Parkinson , ... (NEA), has been appointed to the board of ... twenty years of experience in oncology clinical development, ... that resulted in global approvals of the cancer ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 Synedgen ... Nguyen, PhD as Regulatory Affairs Manager. , Dr. Nguyen ... an important juncture for the company as it moves ... drug products over the next two years. Dr. Nguyen ... of all the regulatory key documents that must be ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - JSS Medical Research Inc., a ... today that it concluded the acquisition of Max Neeman International (MNI), ... Additional regional offices are located in Ahmedabad, Bangalore ... . Through a US subsidiary, a regional office is located ... expansion is supported by the recent equity investment transaction into JSS ...
Breaking Biology Technology:Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4Synedgen Announces the Appointment of Regulatory Affairs Manager 2JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4
... Genzyme,Corporation (Nasdaq: GENZ ) confirmed today that it ... BIVN ) at $5.60 in cash per,outstanding common share ... companies. Genzyme already owns approximately 22 percent of the,outstanding ... 100 percent of its preferred stock that carry a ...
... treatment option for asthma patients not fully controlled on ... ... Calif., Sept. 27 Dey, L.P., an,affiliate of Merck KGaA of ... tablets with its,marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX ). ...
... 27 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... on commercializing proprietary product candidates for the ... that data from,preclinical studies of ANX-514 (docetaxel ... of Cancer Research (AACR), National Cancer,Institute (NCI) ...
Cached Biology Technology:Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 2Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 3Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma 2Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 2ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 4
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... of information, <a target="_blank" href="http://en.wikipedia.org/wiki/Nucleic_acid_sequence,">DNA sequences come ... identify, proof, and discard compromised molecular data has ... endeavor - one that everyone generating sequence data ... sequences for research purposes. "Many researchers find ...
... D.C. Georgetown Lombardi Comprehensive Cancer Center,s Stephen Byers, ... Cancer Institute to address a "provocative question.", The NCI,s ... 24 questions that, if answered, could lead to significant ... such as why obesity contributes to cancer risk ...
... for Autism Research at The Children,s Hospital of Philadelphia ... to identify early signs of autism spectrum disorders (ASD) ... (NIH) Autism Centers of Excellence (ACE) research program. CHOP ... for autism research, which is distributed across nine ACE ...
Cached Biology News:DNA sequences need quality time too - guidelines for quality control published 2Georgetown Lombardi researcher awarded 'Provocative Question' grant from NCI 2Georgetown Lombardi researcher awarded 'Provocative Question' grant from NCI 3CHOP’s Center for Autism Research receives five-year grant as an NIH Autism Center of Excellence 2
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... SYS203 is a complete, flexible system ... small samples, as is frequently required ... designed around Instechs miniature Clark-style polarographic ... inch in diameter (3.2 mm), it ...
... the family of human cullin genes (CUL-1, -2, -3, ... cdc53 gene. Cullin-3 is proposed to be a part ... with cyclin E and targets it for ubiquitination, which ... an activator of cdk2, which leads the cell to ...
... the cost-effective solution for entry level imaging ... research imaging tasks, MetaVue enables time lapse, ... analysis. Compatibility with MetaMorphs extensive and ... has the power to drive motorized microscopes, ...
Biology Products: